Okamoto M, Hinman D J
Subst Alcohol Actions Misuse. 1984;5(2):97-103.
Barbiturate physical dependence was produced by twice-daily administration of Na barbital to cats according to the "low" dose barbiturate protocol (Okamoto et al., J. Pharmacol. Exp. Ther. 207: 906, 1978). The duration of treatment was 1, 2, 3, 5, 9 or 14 weeks. Pharmacodynamic tolerance was assessed by relating the degree of neurofunctional impairment to the blood barbital concentration at the time when the functional test was performed. Evaluation of withdrawal was based on whole-animal observation and subjective assessment of overt withdrawal signs. Motor activity and withdrawal convulsions were monitored continuously by an activity recording device. It was found that the pharmacodynamic tolerance and physical dependence continued to develop throughout the treatment period and no apparent ceiling on these phenomena was observed. The "low" level chronic dosing merely prolonged the time required to develop physical dependence of severity comparable to that produced by shorter durations of "high" level chronic dosing.
根据“低剂量”巴比妥酸盐方案(冈本等人,《药理学与实验治疗学杂志》207: 906,1978年),每天给猫两次注射巴比妥钠,从而产生巴比妥酸盐身体依赖性。治疗持续时间为1、2、3、5、9或14周。通过将神经功能损害程度与进行功能测试时的血液巴比妥浓度相关联,评估药效耐受性。戒断评估基于对整个动物的观察以及对明显戒断症状的主观评估。运动活动和戒断惊厥通过活动记录装置持续监测。研究发现,在整个治疗期间,药效耐受性和身体依赖性持续发展,且未观察到这些现象有明显的上限。“低水平”慢性给药只是延长了产生与较短时间“高水平”慢性给药相当严重程度身体依赖性所需的时间。